Mounjaro 5 mg KwikPen Injection (Tirzepatide) – Prefilled Pen

Mounjaro 5 mg KwikPen Injection contains Tirzepatide, a dual-acting incretin-based injectable medication indicated for the management of Type 2 Diabetes Mellitus. Tirzepatide works by targeting both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors to improve glycemic control.

The 5 mg dose is typically prescribed after successful initiation with the 2.5 mg starting dose. It helps achieve better blood glucose regulation by enhancing insulin secretion, suppressing glucagon release, slowing gastric emptying, and supporting appetite control.

Uses of Mounjaro 5 mg Injection

• Management of Type 2 Diabetes Mellitus

• Improves glycemic control along with diet and exercise

• Helps reduce fasting and post-prandial blood glucose levels

• Maintenance therapy following dose escalation

How Mounjaro Works (Mechanism of Action)

Tirzepatide activates both GIP and GLP-1 receptors, resulting in:

• Increased glucose-dependent insulin secretion

• Decreased glucagon production

• Delayed gastric emptying

• Reduced appetite and caloric intake

These combined actions lead to improved metabolic and glycemic control.

Dosage and Administration

• Route: Subcutaneous injection (abdomen, thigh, or upper arm)

• Recommended Dose: 5 mg once weekly (as prescribed)

• Each pen delivers 4 weekly doses

• Inject on the same day each week, with or without food

• Follow the instructions provided in the package insert

Dose adjustments must be done only under medical supervision.

Side Effects

Common Side Effects:

• Nausea

• Vomiting

• Diarrhea

• Constipation

• Decreased appetite

• Injection site reactions

Serious (Rare) Side Effects:

• Severe gastrointestinal discomfort

• Hypoglycemia (especially when combined with insulin or sulfonylureas)

• Pancreatitis

• Allergic reactions

Seek immediate medical attention if severe or allergic reactions occur.

Precautions and Warnings

• Prescription medicine; use only under doctor supervision

• Not indicated for Type 1 diabetes

• Use caution in patients with gastrointestinal disorders

• Inform your doctor about all ongoing medications

• Not recommended during pregnancy or breastfeeding unless advised

• Do not share the injection pen with others

Storage Instructions

• Store refrigerated at 2°C–8°C

• Do not freeze

• Protect from light

• Follow package insert instructions for storage after first use

Key Highlights

• Contains Tirzepatide 5 mg

• Dual GIP & GLP-1 receptor agonist

• Once-weekly dosing for improved compliance

• Easy-to-use prefilled KwikPen

• Manufactured by Eli Lilly, a globally trusted pharmaceutical company